March 14, 2014 – Sandoz 1 A Pharma is pleased to participate in the develoPPP.de (DPP) project “Quality Assured Essential Medicines for Ghana,” a three-year development partnership aimed at increasing access to high-quality, affordable medicines for pa…
February 17, 2014 – Sandoz has been recognized by various organizations for its achievements in creating an inclusive workplace. …
Holzkirchen, Germany, February 12, 2014 – Sandoz announced it has received marketing authorization in Belgium for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December 18…
Holzkirchen, Germany, February 10, 2014 – Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on Decemb…
Princeton, New Jersey, February 5, 2014 – Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol®.Doxercalciferol injection vials are indicated for the treatment of secondary hyperparath…
Holzkirchen, Germany, February 4, 2014 – Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on Decembe…
February 4, 2014 – Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide ar…
Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December…
Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.The product was first approved in Denmark on December…
Basel, January 29, 2014 – Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.Read the media release …